Tobias A.
- Country
- Germany
- Department
- #40480: Med. Kl. mS. Rheumatologie u. Klin. Immunologie
Research Overview
- Long-Term Safety and Tolerability Assessment of Dapirolizumab Pegol in Patients with Systemic Lupus Erythematosus: A Multicenter, Open-Label Extension Study
- Evaluation of Dapirolizumab Pegol Efficacy and Safety in Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 65 of 93 partner sites.
Specializations
Autoimmune Conditions
The investigator specializes in the study and treatment of IgG4-Related Disease, a complex autoimmune condition affecting multiple organs. Their research focuses on innovative therapeutic approaches for managing this systemic disorder.
- Systemic autoimmune disorders
- Multi-organ inflammatory conditions
- Immunoglobulin-related pathologies
The investigator's work involves evaluating novel biological therapies for autoimmune disease management.
Therapeutic Innovation
Research activities center on investigating subcutaneous administration of innovative treatments for autoimmune conditions, with particular attention to long-term disease management strategies.
- Novel drug delivery methods
- Targeted biological therapies
- Treatment optimization protocols
Their work explores new approaches to maintaining disease remission and preventing disease flares.
Clinical Assessment
The investigator focuses on evaluating treatment efficacy and safety profiles in autoimmune disease interventions, particularly in relation to glucocorticoid therapy management.
- Treatment response monitoring
- Safety assessment protocols
- Long-term disease outcomes
Their research emphasizes comprehensive patient monitoring and therapeutic response evaluation.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.